不活化A型肝炎ワクチンの臨床応用

概要

論文の詳細を見る
A clinical trial was carried out for a lypophilized inactivated hepatitis A vaccine in order to confirm its safety and antibody responce.The vaccine used for the study has been developed by Denka Institute of Biological Science (Lot. D-01), Chiba Serum Institute (Lot. C-01) and The Chemo-Sero-Therapeutic Research Institute (Lot. K-02).Thirty-six volunteers were selected and employed for the present study from healthy male adults carrying no antibody against hepatitis A virus (HAV). They were divided into three dose groups; 1.0μg, 0.5μg and 0.25μg viral protein respectively. Each groups were injected intramuscularly 3 times with 0, 1 and 6 months interval.As the results, though, slight side effects such as local pain were found in 16 cases out of 99 total injected, but no abnormal value was observed in the blood and urine examinations. On the otherhand, the mean values of serum anti-HAV at 2 months after the first injection in 1.0μg, 0.5μg and 0.25μg dose-groups were 562mIU/ml, 323mIU/ml and 134mIU/ml, respectively, and at the 7 months, 3630 mIU/ml, 1288mIU/ml and 1000mIU/ml, respectively. Namely, the high immunogenicity and safety of the vaccine were confirmed in this trail.
財団法人日本消化器病学会の論文